Close Menu

OGT

The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business. 

The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.

The revenue growth comes amid increased demand for the company's molecular genetics products.

Interviews with leading UK scientists revealed apprehension about losing access to European funding, limitations on freedom of movement, and an exodus of biotechs to the EU.

The kit detects the three most common aneuploidies associated with bladder cancer, as well as deletions of the 9p21.3 locus.

Sengenics is rebranding the technology Immunome and expects it to expand the company's footprint in the proteomics space.

The genomic products and services firm said that no assets or personnel will be transferred, but it will license its analysis software to Source BioScience.

The company plans to launch a suite of small cancer panels initially for research, but it could eventually seek regulatory approval for them as diagnostics. 

The arrays feature the addition of newly identified genomic regions, as well as the removal of ones found to have no pathogenic significance.

While there are already many companies in the space, Agilent believes its relatively quick protocol and higher-throughput capacity will set it apart from competitors' products.

Pages

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.